Revvity (RVTY) announced it has entered into a definitive agreement to acquire ACD/Labs. The transaction is expected to close late in Q4.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RVTY:
- Revvity price target raised to $105 from $99 at BofA
- Revvity price target raised to $123 from $122 at Baird
- Revvity price target raised to $105 from $100 at Barclays
- Revvity, Inc. Reports Modest Growth and Strategic Initiatives
- Revvity: Buy Rating Affirmed Amid Strong Q3 Performance and Strategic Positioning